- Cytokinetics (NASDAQ:CYTK) is enjoying a modest upsurge in premarket buying, +14% on modest volume, in apparent reaction to Bristol-Myers Squibb's $13.1B bid for MyoKardia, gaining access to its cardiovascular drug pipeline including lead candidate mavacamten, a modulator of cardiac myosin, a protein that drives heart muscle contraction.
- CYTK's pipeline includes a lineup of candidates for cardiac disorders including lead drug omecamtiv mecarbil for heart failure.
- https://seekingalpha.com/news/3619791-bristol-myers-takeout-of-myokardia-lifts-cytokinetics-up-14
Monday, October 5, 2020
Bristol-Myers takeout of MyoKardia lifts Cytokinetics
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.